Newer Therapies in Rheumatology.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39084836.
- Also identified by DOI 10.1016/j.mcna.2024.02.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Seven of the 11 newer medications recently or soon to be approved to treat rheumatologic diseases discussed in this article are biologic agents and reflect the current ability of science to target specific components of the immune system. The other agents are molecules that are directed against specific immune pathway targets as well. All have shown superiority to placebo and in some cases have been compared to currently accepted therapies. Safety issues are generally centered around infections due to the immune-interrupting nature of these therapies.
Medical subject headings
- Rheumatic Diseases
- Antirheumatic Agents